Characterizing blood‐based biomarkers of AD pathology using both SIMOA and NULISA technologies among Indigenous Africans: Pioneering experience with the VALIANT Cohort

Abstract

Background: Biofluid biomarkers in Alzheimer's disease and related dementia (ADRD) research is in infancy in Africa. Most existing data come from populations in the Global North, where risk factors and comorbidities differ from those in the Global South.